EU Approval Urged for New Sanofi ERT Avalglucosidase Alfa

EU Approval Urged for New Sanofi ERT Avalglucosidase Alfa

300815

EU Approval Urged for New Sanofi ERT Avalglucosidase Alfa

A committee of the European Medicines Agency (EMA) has recommended the approval of avalglucosidase alfa, a next-generation enzyme replacement therapy (ERT) developed by Sanofi Genzyme, for people with Pompe disease. That recommendation, by the Committee for Medicinal Products for Human Use (CHMP), paves the way for marketing authorization to be granted by the European Commission for avalglucosidase alfa as a treatment for Pompe. According to an EMA press release, avalglucosidase alfa — to be marketed as Nexviadyme — will…

You must be logged in to read/download the full post.